Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Cited by (1,079)

Items 901–1,000 of 1,079

1. PIK3CA Cooperates with Other Phosphatidylinositol 3′-Kinase Pathway Mutations to Effect Oncogenic Transformation
   Katsutoshi Oda, Jennifer Okada, Luika Timmerman, Pablo Rodriguez‐Viciana, David Stokoe, Keiko Shoji, Yuji Taketani, Hiroyuki Kuramoto, Zachary A. Knight, Kevan M. Shokat et al. · 2008 · Cancer Research
2. Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations
   Satoshi Morita, Isamu Okamoto, Kunihiko Kobayashi, Koichi Yamazaki, Hajime Asahina, Akira Inoue, Koichi Hagiwara, Noriaki Sunaga, Noriko Yanagitani, Toyoaki Hida et al. · 2009 · Clinical Cancer Research
3. Detection ofEGFRGene Mutation in Lung Cancer by Mutant-Enriched Polymerase Chain Reaction Assay
   Hiroaki Asano, Shinichi Toyooka, Masaki Tokumo, Kouichi Ichimura, Keisuke Aoe, Sachio Ito, Kazunori Tsukuda, Mamoru Ouchida, Motoi Aoe, Hideki Katayama et al. · 2006 · Clinical Cancer Research
4. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology
   Amit J. Sabnis, Trever Grant Bivona · 2019 · Trends in Molecular Medicine
5. Epidermal Growth Factor–Independent Transformation of Ba/F3 Cells with Cancer-Derived Epidermal Growth Factor Receptor Mutants Induces Gefitinib-Sensitive Cell Cycle Progression
   Jingrui Jiang, Heidi E. Greulich, Pasi Antero Janne, William R. Sellers, Matthew M. Meyerson, James D. Griffin · 2005 · Cancer Research
6. Perturbation Biology: Inferring Signaling Networks in Cellular Systems
   Evan J. Molinelli, Anil Korkut, Weiqing Wang, Martin L. Miller, Nicholas Paul Gauthier, Xiaohong Jing, Poorvi Kaushik, Qin He, Gordon Brent Mills, David B. Solit et al. · 2013 · PLoS Computational Biology
7. Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy
   Gur Pines, Wolfgang J. Köstler, Yosef Yarden · 2010 · FEBS Letters
8. MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
   Kazuhiro Kitamura, Masahiro Seike, Tetsuya Okano, Kuniko Matsuda, Akihiko Miyanaga, Hideaki Mizutani, Rintaro Noro, Yuji Minegishi, Kaoru Kubota, Akihiko Gemma · 2013 · Molecular Cancer Therapeutics
9. Minimally Invasive Pharmacokinetic and Pharmacodynamic Technologies in Hypothesis-Testing Clinical Trials of Innovative Therapies
   Paul Workman, Eric Ofori Aboagye, Yuen‐Li Chung, John Richard Griffiths, Rachel Hart, Martin O. Leach, Ross J. Maxwell, Paul M.J. McSheehy, Pat Price, Jamal Zweit · 2006 · JNCI Journal of the National Cancer Institute
10. Lung Cancer in the Era of Precision Medicine
    Katerina A. Politi, Roy S. Herbst · 2015 · Clinical Cancer Research
11. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis
    Nikolas Hendrik Stoecklein, Christoph A. Klein · 2009 · International Journal of Cancer
12. Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China
    Yi-Long Lung Cancer Wu, Wen‐Zhao Zhong, Long-Yun Li, Xiao-Tong Zhang, Li Zhang, Cai-Cun Zhou, Wei Liu, Bin Jiang, Xin-Lin Mu, Jia-Ying Lin et al. · 2007 · Journal of Thoracic Oncology
13. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
    Sai‐Hong Ignatius Ou · 2011 · Drug Design Development and Therapy
14. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells
    Zhenfeng Zhang, Susumu S. Kobayashi, Alain Borczuk, Rom S. Leidner, Thomas LaFramboise, Alan D. Levine, Balázs Halmos · 2010 · Carcinogenesis
15. MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA
    Minjun Du, Yanjiao Zhang, Yousheng Mao, Juwei Mou, Jun Zhao, Qi Xue, Dali Wang, Jinfeng Huang, Shugeng Gao, Yushun Gao · 2016 · Biochemical and Biophysical Research Communications
16. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.
    Cortot, Alexis B., Repellin, Claire E., Shimamura, Takeshi, Capelletti, Marzia, Zejnullahu, Kreshnik, Ercan, Dalia, Christensen, James G., Wong, Kwok-Kin, Gray, Nathanael S., Jänne, Pasi A. · 2013 · Cancer Research
17. Evolution of platinum resistance in high-grade serous ovarian cancer
    Cooke, Susanna L, Brenton, James D · 2011 · The Lancet Oncology
18. A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer
    Yasushi Yatabe, Toyoaki Hida, Yoshitsugu Horio, Takayuki Kosaka, Takashi Takahashi, Tetsuya Mitsudomi · 2006 · Journal of Molecular Diagnostics
19. EGFR Signaling in Colorectal Carcinoma
    Alyssa M. Krasinskas · 2011 · Pathology Research International
20. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
    Bin-Chi Liao, Jih‐Hsiang Lee, Chia‐Chi Lin, Ya‐Fang Chen, Chin‐Hao Chang, Chao‐Chi Ho, Jin‐Yuan Shih, Chong‐Jen Yu, James Chih‐Hsin Yang · 2015 · Journal of Thoracic Oncology
21. Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019)
    Parth Bhatia, Vrinda Sharma, Ozair Alam, Ajay Manaithiya, Perwaiz Alam, Kahksha, Md Tauquir Alam, Mohd Imran · 2020 · European Journal of Medicinal Chemistry
22. Lung cancer in never smokers: Disease characteristics and risk factors
    Athanasios G. Pallis, Konstantinos Nikolaos Syrigos · 2013 · Critical Reviews in Oncology/Hematology
23. Current Landscape of Targeted Therapy in Lung Cancer
    Manasi K. Mayekar, Trever Grant Bivona · 2017 · Clinical Pharmacology & Therapeutics
24. Phase II Trial of Cetuximab in Patients With Previously Treated Non–Small-Cell Lung Cancer
    Nasser H. Hanna, Rogério Lilenbaum, Rafat Ansari, Thomas James Lynch, Ramaswamy Govindan, Pasi Antero Janne, Philip Bonomi · 2006 · Journal of Clinical Oncology
25. Frequency of and variables associated with the EGFR mutation and its subtypes
    Tomoaki Tanaka, Masaru Matsuoka, Akihisa Sutani, Akihiko Gemma, Makoto Maemondo, Akira Inoue, Shoji Okinaga, Makoto Nagashima, Satoshi Oizumi, Kazutsugu Uematsu et al. · 2009 · International Journal of Cancer
26. Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cells Bearing EGFR Gene Mutation and Amplification
    Takafumi Okabe, Isamu Okamoto, Kenji Tamura, Masaaki Terashima, Takeshi Yoshida, Taroh Satoh, Minoru Takada, Masahiro Fukuoka, Kazuhiko Nakagawa · 2007 · Cancer Research
27. Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
    Soundararajan Krishnaswamy, Rajani Kanteti, Jonathan S. Duke‐Cohan, Sivakumar Loganathan, Wanqing Liu, Patrick C. Ma, Martin Sattler, Patrick A. Singleton, Nithya Ramnath, Federico Innocenti et al. · 2009 · Clinical Cancer Research
28. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence
    Ou, Sai-Hong Ignatius · 2012 · Critical Reviews in Oncology/Hematology
29. Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models
    Jill M. Spoerke, Carol Lynn O'Brien, Ling Y. Huw, Hartmut Koeppen, Jane Fridlyand, Rainer Karl Brachmann, Peter M. Haverty, Ajay Pandita, Sankar Mohan, Deepak Sampath et al. · 2012 · Clinical Cancer Research
30. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
    Yu, H.A., Arcila, M.E., Hellmann, M.D., Kris, M.G., Ladanyi, M., Riely, G.J. · 2014 · Annals of Oncology
31. Frequent EGFR mutations in brain metastases of lung adenocarcinoma
    Shingo Matsumoto, Kenji Takahashi, Reika Iwakawa, Yoshihiro Matsuno, Yukihiro Nakanishi, Takashi Kohno, Eiji Shimizu, Jun Yokota · 2006 · International Journal of Cancer
32. Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST
    Mizuki Nishino, Jyothi Priya Jagannathan, Katherine Maragaret Krajewski, Kevin N. O'Regan, Hiroto Hatabu, Geoffrey Ira Shapiro, Nikhil H. Ramaiya · 2012 · American Journal of Roentgenology
33. Cellular responses to EGFR inhibitors and their relevance to cancer therapy
    Pinaki R Dutta, Amit M. Maity · 2007 · Cancer Letters
34. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
    Ying Cheng, Haruyasu Murakami, Pan‐Chyr Yang, Jianxing He, Kazuhiko Nakagawa, Jin Hyoung Kang, Joo-Hang Kim, Xin Wang, Sotaro Enatsu, Tarun Puri et al. · 2016 · Journal of Clinical Oncology
35. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma
    Sudhanshu Kumar Shukla, Joseph R. Evans, Rohit Malik, Felix Yi-Chung Feng, Saravana Mohan Dhanasekaran, Xuhong Cao, Guoan Chen, David G. Beer, Hui Jiang, Arul M. Chinnaiyan · 2016 · JNCI Journal of the National Cancer Institute
36. Icotinib versus whole-brain irradiation in patients with EGFR -mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial
    Jin‐Ji Yang, Caicun Zhou, Yi-Sheng Huang, Jifeng Feng, Lu Sun, Yong Song, Cheng Huang, Gang Wu, Li Zhang, Ying Cheng et al. · 2017 · The Lancet Respiratory Medicine
37. Mutational analysis of the <i>HER2</i> gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features
    Buttitta, Fiamma, Barassi, Fabio, Fresu, Giuseppina, Felicioni, Lara, Chella, Antonio, Paolizzi, Diego, Lattanzio, Giuseppe, Salvatore, Simona, Camplese, Pier P., Rosini, Sandra et al. · 2006 · International Journal of Cancer
38. ALK inhibitors in the treatment of advanced NSCLC
    Cesare Gridelli, Solange Peters, Assunta Sgambato, Francesca Casaluce, Alex A. Adjei, Fortunato Ciardiello · 2013 · Cancer Treatment Reviews
39. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: Molecular bases for EGFR-targeted therapy
    Pablo Uribe, Sergio González · 2011 · Pathology - Research and Practice
40. Role of tumor markers in patients with solid cancers: A critical review
    Michael Joe Duffy · 2007 · European Journal of Internal Medicine
41. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
    Ymera Pignochino, Giovanni Grignani, Giuliana Cavalloni, Manuela Motta, Marta Tapparo, Stefania Bruno, Alessia Bottos, Loretta Gammaitoni, Giorgia Migliardi, Giovanni Camussi et al. · 2009 · Molecular Cancer
42. Prediction of Resistance to Small Molecule FLT3 Inhibitors
    Jan Cools, Nicole Mentens, Pascal Furet, Doriano Fabbro, Jennifer Clark, James D. Griffin, Peter Marynen, Dwight Gary Gilliland · 2004 · Cancer Research
43. Beclin orthologs: integrative hubs of cell signaling, membrane trafficking, and physiology
    Beth Levine, Rong Liu, Xiaonan Dong, Qing Zhong · 2015 · Trends in Cell Biology
44. Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase
    Ludovico Sutto, Francesco Luigi Gervasio · 2013 · Proceedings of the National Academy of Sciences
45. Phosphoproteomics in cancer
    Harsha Gowda, Akhilesh Pandey · 2010 · Molecular Oncology
46. EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms
    Michael A. Baumann, Mechthild Krause, Ekkehard Dikomey, Klaus Dittmann, Wolfgang Dörr, Ulla Kasten-Pisula, H. Peter Rodemann · 2007 · Radiotherapy and Oncology
47. A framework for identification of actionable cancer genome dependencies in small cell lung cancer
    Martin L. Sos, Felix Dietlein, Martin Peifer, Jakob Schöttle, Hyatt Balke‐Want, Christian Müller, Mirjam Koker, André Richters, Stefanie Heynck, Florian Malchers et al. · 2012 · Proceedings of the National Academy of Sciences
48. Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel
    Ayana Sawai, Sarat Chandarlapaty, Heidi E. Greulich, Mithat Gönen, Qing Ye, Carlos L. Arteaga, William R. Sellers, Neal X. Rosen, David B. Solit · 2008 · Cancer Research
49. The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
    Young-Wook Kim, Jeonghun Ko, Zheng-Yun Cui, Amir Abolhoda, Jin Seok Ahn, Sai-Hong Ou, Myung‐Ju Ahn, Keunchil Park · 2012 · Molecular Cancer Therapeutics
50. Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non–Small-Cell Lung Cancer
    George R. Simon, Anupama Sharma, Xueli Li, Todd Richard Hazelton, Frank W. Walsh, Charles C. Williams, Alberto Chiappori, Eric B. Haura, Tawee Tanvetyanon, Scott Joseph Antonia et al. · 2007 · Journal of Clinical Oncology
51. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
    Masayuki Takeda, Isamu Okamoto, Kazuhiko Nakagawa · 2015 · Lung Cancer
52. Catalytic Mechanisms and Regulation of Protein Kinases
    Zhihong Wang, Philip A. Cole · 2014 · Methods in enzymology on CD-ROM/Methods in enzymology
53. Switching on kinases: oncogenic activation of BRAF and the PDGFR family
    Nick J. Dibb, Stephen M. Dilworth, Clifford D. Mol · 2004 · Nature reviews. Cancer
54. Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations
    Hata, Akito, Katakami, Nobuyuki, Yoshioka, Hiroshige, Takeshita, Jumpei, Tanaka, Kosuke, Nanjo, Shigeki, Fujita, Shiro, Kaji, Reiko, Imai, Yukihiro, Monden, Kazuya et al. · 2013 · Cancer
55. Digital PCR analysis of circulating nucleic acids
    Irena Hudecova · 2015 · Clinical Biochemistry
56. A genetic basis for the variation in the vulnerability of cancer to DNA damage
    Brian D. Yard, Drew Adams, Eui Kyu Chie, Pablo Tamayo, Jessica Battaglia, Priyanka Gopal, Kevin R. Rogacki, Bradley E. Pearson, James G. Phillips, Daniel Philip Raymond et al. · 2016 · Nature Communications
57. Drug development in oncology: classical cytotoxics and molecularly targeted agents
    Shivaani Kummar, Martin E Gutierrez, James H. Doroshow, Anthony J. Murgo · 2006 · British Journal of Clinical Pharmacology
58. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
    Russo, Alessandro, Franchina, Tindara, Rita Ricciardi, Giuseppina Rosaria, Picone, Antonio, Ferraro, Giuseppa, Zanghì, Mariangela, Toscano, Giuseppe, Giordano, Antonio, Adamo, Vincenzo · 2015 · Oncotarget
59. EGFRMutation Conferring Primary Resistance to Gefitinib in Non–Small-Cell Lung Cancer
    Jin‐Yuan Shih, Chien‐Hung Gow, Pan‐Chyr Yang · 2005 · New England Journal of Medicine
60. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors
    John Lindsay Marshall · 2006 · Cancer
61. Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
    Vienna Ludovini, Fortunato Bianconi, Lorenza Pistola, Rita Chiari, Vincenzo Minotti, Renato Colella, Dario Giuffrida, Francesca Romana Tofanetti, Annamaria Siggillino, Antonella Flacco et al. · 2011 · Journal of Thoracic Oncology
62. Noninvasive Saliva-based EGFR Gene Mutation Detection in Patients with Lung Cancer
    Fang Wei, Chien‐Chung Lin, Aron Y. Joon, Ziding Feng, Gabriel E. Troche, Maruja E. Lira, David Chia, Mao Mao, Chung‐Liang Ho, Wu‐Chou Su et al. · 2014 · American Journal of Respiratory and Critical Care Medicine
63. Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy
    M. Michael, Margaret M. Doherty · 2004 · Journal of Clinical Oncology
64. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
    Shuji Ogino, Charles S. Fuchs, Edward L. Giovannucci · 2012 · Expert Review of Molecular Diagnostics
65. Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors
    Shigenari Nukaga, Hiroyuki Yasuda, Katsuya Tsuchihara, Junko Hamamoto, Keita Masuzawa, Ichiro Kawada, Katsuhiko Naoki, Shingo Matsumoto, Sachiyo Mimaki, Shinnosuke Ikemura et al. · 2017 · Cancer Research
66. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
    Carol A. Townsley, Pierre P Major, Lillian L. Siu, Janet Ellen Dancey, ELAINE CHEN, Gregory R. Pond, Trudey Nicklee, Jcm Ho, David William Hedley, Ming‐Sound Tsao et al. · 2006 · British Journal of Cancer
67. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.
    Su, Zengliu, Dias-Santagata, Dora, Duke, MarKeesa, Hutchinson, Katherine, Lin, Ya-Lun, Borger, Darrell R., Chung, Christine H., Massion, Pierre P., Vnencak-Jones, Cindy L., Iafrate, A. John et al. · 2011 · The Journal of Molecular Diagnostics
68. The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations
    Heon, Stephanie, Yeap, Beow Y., Lindeman, Neal I., Joshi, Victoria A., Butaney, Mohit, Britt, Gregory J., Costa, Daniel B., Rabin, Michael S., Jackman, David M., Johnson, Bruce E. · 2012 · Clinical Cancer Research
69. Epidermal Growth Factor Receptor in Triple-Negative and Basal-Like Breast Cancer
    Monika Leigh Burness, Tatyana A. Grushko, Olufunmilayo Ibironke Olopade · 2010 · The Cancer Journal
70. Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes
    Hyun-Ju Lee, Young Tae Kim, Chang Hyun Kang, Binsheng Zhao, Yongqiang Tan, Lawrence Howard Schwartz, Thorsten Persigehl, Yoon Kyung Jeon, Doo Hyun Chung · 2013 · Radiology
71. Sequence Variations of MicroRNAs in Human Cancer: Alterations in Predicted Secondary Structure Do Not Affect Processing
    Sven Diederichs, Daniel A. Haber · 2006 · Cancer Research
72. Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis
    Yang Zhang, Yihua Sun, Yunjian Pan, Chenguang Li, Lei Shen, Yuan Li, Xiaoyang Luo, Ting Ye, Rui Wang, Haichuan Hu et al. · 2012 · Clinical Cancer Research
73. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results
    Michael A. Baumann, Mechthild Krause · 2004 · Radiotherapy and Oncology
74. Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2
    Rogério Lilenbaum, Rita Susan Axelrod, Sachdev P. Thomas, Afshin Dowlati, L. Seigel, Donald Albert, Karsten Witt, David Botkin · 2008 · Journal of Clinical Oncology
75. Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer
    Kim, Hyun Seok, Mendiratta, Saurabh, Kim, Jiyeon, Pecot, Chad Victor, Larsen, Jill E., Zubovych, Iryna, Seo, Bo Yeun, Kim, Jimi, Eskiocak, Banu, Chung, Hannah et al. · 2013 · Cell
76. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
    Helmout Modjtahedi, Sharadah Essapen · 2009 · Anti-Cancer Drugs
77. Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
    Grzegorz J. Korpanty, Donna M. Graham, Mark David Vincent, Natasha B. Leighl · 2014 · Frontiers in Oncology
78. Pharmacogenetics in drug discovery and development: a translational perspective
    Allen D. Roses · 2008 · Nature Reviews Drug Discovery
79. Targeting ALK in neuroblastoma—preclinical and clinical advancements
    Erica L. Carpenter, Yaël P. Mossé · 2012 · Nature Reviews Clinical Oncology
80. GPCRs: Emerging anti-cancer drug targets
    Ainhoa Nieto, Patricia H. McDonald · 2017 · Cellular Signalling
81. The mannose-binding lectin: a prototypic pattern recognition molecule
    Kazue Takahashi, WK Eddie Ip, Ian C. Michelow, R. Alan B. Ezekowitz · 2005 · Current Opinion in Immunology
82. Predictive Markers in Breast and Other Cancers: A Review
    Michael Joe Duffy · 2005 · Clinical Chemistry
83. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours
    Marc‐Eric Halatsch, Ursula I. Schmidt, Julianne Behnke‐Mursch, Andreas Wilhelm Unterberg, Christian Rainer Wirtz · 2006 · Cancer Treatment Reviews
84. The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance
    Meng‐Shih Weng, Jer‐Hwa Chang, Wen-Yueh Hung, Yi‐Chieh Yang, Ming‐Hsien Chien · 2018 · Journal of Experimental & Clinical Cancer Research
85. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
    Ymera Pignochino, Ivana Sarotto, Caterina Peraldo Neia, Junia Yara Penachioni, Giuliana Cavalloni, Giorgia Migliardi, Laura Casorzo, Giovanna Chiorino, Mauro Risio, Alberto Bardelli et al. · 2010 · BMC Cancer
86. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
    Soji Kakiuchi, Yataro Daigo, Nobuhisa Ishikawa, Chiyuki Furukawa, Tatsuhiko Tsunoda, Seiji Yano, Kazuhiko Nakagawa, Takashi Tsuruo, Nobuoki Kohno, Masahiro Fukuoka et al. · 2004 · Human Molecular Genetics
87. Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling
    Tian-Ying Jia, Jun-Feng Xiong, Xiaoyang Li, Wen Juan Yu, Zhiyong Xu, Xu‐Wei Cai, Jingchen Ma, Yacheng Ren, Rasmus Larsson, Jie Zhang et al. · 2019 · European Radiology
88. Multigene amplification and massively parallel sequencing for cancer mutation discovery
    Fredrik Dahl, Johan Stenberg, Simon Fredriksson, Katrina M. Welch, Michael Zhang, Mats F. Nilsson, David Bicknell, Walter Fred Bodmer, Ronald Wayne Davis, Hanlee P. Ji · 2007 · Proceedings of the National Academy of Sciences
89. Proteins, drug targets and the mechanisms they control: the simple truth about complex networks
    Robyn P. Araujo, Lance A. Liotta, Emanuel F. Petricoin · 2007 · Nature Reviews Drug Discovery
90. Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
    Chen, Shih-Hsun, Zhang, Youyan, Van Horn, Robert D., Yin, Tinggui, Buchanan, Sean, Yadav, Vipin, Mochalkin, Igor, Wong, Swee Seong, Yue, Yong Gang, Huber, Lysiane et al. · 2016 · Cancer Discovery
91. Effects of Erlotinib in <i>EGFR</i> Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
    Costa, Daniel B., Nguyen, Kim-Son H., Cho, Byoung C., Sequist, Lecia V., Jackman, David M., Riely, Gregory J., Yeap, Beow Y., Halmos, Balázs, Kim, Joo H., Jänne, Pasi A. et al. · 2008 · Clinical Cancer Research
92. Mitochondria: gatekeepers of response to chemotherapy
    Kristopher A. Sarosiek, Tríona Ní Chonghaile, Anthony G. Letai · 2013 · Trends in Cell Biology
93. Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications
    Charles M. Rudin, Érika Ávila-Tang, Curtis C. Harris, James Gordon Herman, Fred R. Hirsch, William J. Pao, Ann G. Schwartz, Kirsi Vähäkangas, Jonathan M. Samet · 2009 · Clinical Cancer Research
94. HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
    Michael F. Press, Richard S. Finn, David Cameron, Angelo Di Leo, Charles E. Geyer, Ivonne E. Villalobos, Angela Santiago, Roberta Guzman, Armen Gasparyan, Yanling Ma et al. · 2008 · Clinical Cancer Research
95. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer
    Umberto Malapelle, Rafael Sirera, Eloisa Jantus Lewintre, Pablo Reclusa, Silvia Calabuig Fariñas, Ana Blasco, Pasquale Pisapia, Christian Diego Rolfo, Carlos Camps · 2017 · Expert Review of Molecular Diagnostics
96. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials
    Zhenyi Niu, Runsen Jin, Yan Zhang, Hecheng Li · 2022 · Signal Transduction and Targeted Therapy
97. A Functional Common Polymorphism in a Sp1 Recognition Site of the Epidermal Growth Factor Receptor Gene Promoter
    Wanqing Liu, Federico Innocenti, Michael H. Wu, Apurva A. Desai, M. Eileen Dolan, Edwin H. Cook, Mark J. Ratain · 2005 · Cancer Research
98. Targeted inhibition of EGFR and glutaminase induces metabolic crisis in EGFR mutant lung cancer
    Momcilovic, Milica, Bailey, Sean T., Lee, Jason T., Fishbein, Michael C., Magyar, Clara, Braas, Daniel, Graeber, Thomas, Jackson, Nicholas J., Czernin, Johannes, Emberley, Ethan et al. · 2017 · Cell Reports
99. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
    Jin‐Yuan Shih, Chien‐Hung Gow, Chong‐Jen Yu, Chih‐Hsin Yang, Yih‐Leong Chang, Meng‐Feng Tsai, Ya‐Chieh Hsu, Kuan‐Yu Chen, Wen‐Pin Su, Pan‐Chyr Yang · 2005 · International Journal of Cancer
100. Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy
     Kancha, Rama Krishna, von Bubnoff, Nikolas, Peschel, Christian, Duyster, Justus · 2009 · Clinical Cancer Research